<DOC>
	<DOCNO>NCT02659397</DOCNO>
	<brief_summary>The purpose research study measure amount atorvastatin ETC-1002 blood , determine ETC-1002 affect level LDL-cholesterol ( bad cholesterol ) markers health disease blood urine , see ETC-1002 tolerate body compare placebo add stable atorvastatin 80 mg background therapy statin-treated patient .</brief_summary>
	<brief_title>A Study Of Pharmacokinetics , Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>Taking daily stable statin dos least 4 week prior screen visit . LDLC 100220 mg/dL patient take daily highintensity statin ( 4 week prior switch sponsor provide atorvastatin 80 mg/day stop lipidregulating drug supplement ) screen visit ; , LDLC 115220 mg/dL patient take moderate lowintensity statin ( 4 week prior switch sponsor provide atorvastatin 80 mg/day stop lipidregulating drug supplement ) screen visit . Must willing discontinue lipidregulating therapy study History acute significant cardiovascular disease . Current clinically significant cardiovascular disease . History inability tolerate statin dose due musclerelated pain weakness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>LDL-cholesterol</keyword>
	<keyword>Hypercholesterolemia</keyword>
	<keyword>ETC-1002</keyword>
	<keyword>Adenosine triphosphate citrate lyase</keyword>
	<keyword>Atorvastatin</keyword>
</DOC>